title: PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY.
abstract: OBJECTIVE
  To report reactivation rate after bevacizumab treatment for retinopathy of prematurity (ROP) in eyes with classic ROP (CROP) versus aggressive posterior ROP (APROP) and to report peripheral fluorescein angiography findings in these eyes.
  
  
  METHODS
  Retrospective chart review was conducted on consecutive infants treated with bevacizumab for ROP, followed by fluorescein angiography and prophylactic laser to persistent avascular retina.
  
  
  RESULTS
  Sixty-four eyes of 33 patients were included. Mean gestational age was 25 weeks with mean birth weight of 674 g. Mean follow-up was 125 weeks post-menstrual age (PMA). Reactivation requiring treatment after initial bevacizumab was more common in eyes with APROP (8/16) than with CROP (2/48; P < 0.0001). At mean 73 weeks PMA, eyes with APROP had more avascular retina (mean 4.4 disk diameters vs. 2.6 disk diameters; P = 0.0004) and higher percentage of leakage (11/11 eyes vs. 22/38 eyes; P = 0.01) on fluorescein angiography than in eyes with CROP. Unfavorable outcome occurred in 1 of 16 eyes with APROP and in no eyes with CROP. No eye that underwent prophylactic laser after bevacizumab had a poor structural outcome.
  
  
  CONCLUSIONS
  In our study, bevacizumab-treated eyes with APROP have a higher likelihood of recurrence and larger area of persistent nonperfusion than in eyes with CROP. Treatment of ROP with bevacizumab followed by prophylactic laser has a low rate of unfavorable structural outcome.
authors.affiliation: Retina Consultants, Ltd, Des Plaines, Illinois.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Garcia Gonzalez
authors.affiliation: Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois.
authors.forename: Laura
authors.initials: L
authors.lastname: Snyder
authors.affiliation: Retina Consultants, Ltd, Des Plaines, Illinois.|Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois.
authors.forename: Michael
authors.initials: M
authors.lastname: Blair
authors.affiliation: Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois.
authors.forename: Ashley
authors.initials: A
authors.lastname: Rohr
authors.affiliation: Retina Consultants, Ltd, Des Plaines, Illinois.
authors.forename: Michael
authors.initials: M
authors.lastname: Shapiro
authors.affiliation: Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois.
authors.forename: Mark
authors.initials: M
authors.lastname: Greenwald
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007223:Infant; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D012008:Recurrence; D012178:Retinopathy of Prematurity / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab